News

FDA approves Kerendia for heart failure with ejection fraction of 40% or higher
Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...
Pharmabiz3h
US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%
US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%: Berlin Wednesday, July 16, 2025, 13:00 H ...
Medical Dialogues3h
FDA Expands Finerenone Indication to Include Heart Failure
The FDA has broadened the approved use of finerenone (Kerendia) to include treatment for heart failure, according to an ...
Daily Jang21h
FDA approves Kerendia for cardiac failure with LVEF ≥40 percent
In a significant move, the U.S. Food and Drug Administration granted approval for Kerendia for patients with heart failure ...
PMLive1h
Bayer’s Kerendia granted FDA approval for new heart failure indication
Bayer’s Kerendia (finerenone) has been approved by the US Food and Drug Administration (FDA) to treat heart failure (HF) patients with left ventricular ejection fraction (LVEF) of at least 40%.
AHA/ASA Journals17h
The Promise and Peril of Learning Algorithms and Predictive Models in Clinical Decision Support: Be Careful What You Train For
The era of predictive modeling enhanced with machine learning and artificial intelligence (AI) to aid clinical ...
The Brighterside of News on MSN13h
Weight-loss drug Tirzepatide significantly slows breast cancer growth, study finds
Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.
The BMJ32m
Dealing with continuous variables and modelling non-linear associations in healthcare data: practical guide
Proper handling of continuous variables is crucial in healthcare research, for example, within regression modelling for descriptive, explanatory, or predictive purposes. However, inadequate methods ...